Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
WESTLAKE VILLAGE, Calif., Jan. 04, 2018 -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference, Wednesday, Jan. 10, 2018, 11:30 a.m. PST, in San Francisco.
The presentation will be webcast live and can be accessed through the Investor Relations section of the Company’s website at Investors.SiennaBio.com. An archived version of the webcast will be available approximately two hours following the live presentation for 90 days.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The Company’s objective is to develop an innovative, diversified, multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients. Sienna is led by a management team with extensive experience in product development and commercialization at several leading dermatology, aesthetics and biotechnology companies.
For more information, visit the Company’s website at www.SiennaBio.com.
Contact (Investors and Media):
Ric Peterson
Chief Financial Officer
[email protected]
818-629-2232
Sean Andrews
Senior Director, Investor Relations
[email protected]
818-629-2244
